Accelerate smarter with early-phase insights across regions. This edition explores how Medtech and Biopharma innovators are advancing from early feasibility to regulatory submission—while leveraging global strategies that work: Navigate the FDA’s new rare disease pathways for CGTs.
first-in-human · regulatory · FDA · MedTech · biopharma · approval
Accelerate smarter with early-phase insights across regions.
This edition explores how Medtech and Biopharma innovators are advancing from early feasibility to regulatory submission—while leveraging global strategies that work:
The FDA has released three new draft guidances aimed at accelerating the development of cell and gene therapies for rare diseases. Sponsors are encouraged to use adaptive designs, external controls, and real-world data—especially in small, underserved populations where traditional trial models may fall short.
This shift paves the way for more inclusive, innovative early-phase trials—particularly relevant for emerging regions like U.S. regulatory anchoring plus U.S. and Latin America execution, where smaller populations and lower competition make real-world strategies more practical and powerful.
Source: ropesgray.com
From regulatory oversight to data integrity, there are ten foundational controls that research leaders should prioritize to ensure trial success—especially in early-phase studies. These include ethical safeguards, adaptive design principles, and robust digital infrastructure to support decentralized models.
Early-phase trials thrive on precision, agility, and operational clarity. Applying these controls not only reduces risk but also accelerates timelines—especially when entering fast-moving or resource-variable markets.
Source: www.bioaccessla.com
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Advances in device and therapeutic development are converging with more sophisticated go-to-market frameworks. As global systems shift toward accelerated access and value-based evaluation, innovators are gaining traction through earlier alignment between R&D, clinical trial strategy, and regional regulatory readiness.
Source: bakermckenzie.com
A next-generation hybrid stent graft system designed for challenging aortic arch pathologies has entered its pivotal clinical evaluation. The study marks the first human use of a self-expanding stent graft with a dedicated left subclavian artery (LSA) branch, intended for use in frozen elephant trunk procedures—an area of high unmet clinical need.
Highly specialized device trials like this one underscore the need for meticulous site selection, surgeon training, and post-procedural follow-up infrastructure. As trial complexity rises, sponsors are increasingly evaluating alternative geographies that offer both procedural expertise and operational flexibility—unlocking new pathways for running efficient, high-stakes studies without bottlenecks.
Source: www.medicaldevice-network.com
A sweeping regulatory reform from the European Union aims to accelerate patient access to innovative oncology drugs across member states. By replacing fragmented national health technology assessments (HTAs) with a centralized EU-level review process, the initiative intends to create a more unified, predictable pathway for evaluating clinical benefit and cost-effectiveness.
Source: www.medscape.com
A novel surgical device designed for soft-tissue procedures has moved from early feasibility to FDA submission following its first-in-human use. The technology, developed through an accelerator pathway, reflects a growing trend of streamlined transitions between early clinical validation and regulatory advancement—particularly in the minimally invasive surgery space.
Source: sofinnovapartners.com
← All Global Trial Accelerators editions · Contact bioaccess®